Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited Total Non-Current Liabilities for the year ending March 31, 2024: USD 24.60 M

Marksans Pharma Limited Total Non-Current Liabilities is USD 24.60 M for the year ending March 31, 2024, a 139.78% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Marksans Pharma Limited Total Non-Current Liabilities for the year ending March 31, 2023 was USD 10.26 M, a 27.90% change year over year.
Marksans Pharma Limited Total Non-Current Liabilities for the year ending March 31, 2022 was USD 8.02 M, a 139.75% change year over year.
Marksans Pharma Limited Total Non-Current Liabilities for the year ending March 31, 2021 was USD 3.35 M, a -10.04% change year over year.
Marksans Pharma Limited Total Non-Current Liabilities for the year ending March 31, 2020 was USD 3.72 M, a 40.59% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Personal Care

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years